{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:31:13Z","timestamp":1785421873794,"version":"3.56.0"},"reference-count":12,"publisher":"SAABRON PRESS","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Daratumumab is increasingly incorporated into the standard treatment regimens for patients with plasma cell dyscrasias in Asia, especially with cost-containment measures implemented by various regional health authorities. This analysis aimed to study daratumumab\u2019s tolerability amongst Asian patients. This is a retrospective medical records review of patients who received daratumumab between November 2016 and August 2021 as part of routine clinical care. Sixty-two patients were included in the study: 62.9% had renal impairment, and 27.4% had creatinine clearance (CrCl) &lt;30ml\/min. Forty-five patients (72.6%) received daratumumab combination therapy, with a median 1 line of prior therapy. The median duration of follow-up was 12.4 months, and the median duration patients were on treatment with daratumumab was 12.3 months. Twenty-one of 62 (33.9%) patients experienced infusion-related reactions (IRRs) after the first dose of intravenous daratumumab. Seven developed mostly grades 1 and 2 respiratory events, and 14 showed grades 1 and 2 non-respiratory IRRs. Only one patient experienced a grade 1 IRR with the second infusion, with none developing any IRRs in the third or subsequent infusions. Eight (12.9%) patients were affected by hematological adverse events (AEs), mostly grades 2 and 3, with one experiencing grade-4 neutropenia without sepsis. Six (9.7%) patients experienced non-hematological AEs, the commonest being pneumonia and other infections, with one developing Nocardia pneumonia (grade 4) 14 months after the initiation of daratumumab. In conclusion, daratumumab is tolerable amongst Asian patients, including the elderly, and patients with severe renal impairment and chronic lung diseases.<\/jats:p>","DOI":"10.46989\/001c.92085","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T09:37:14Z","timestamp":1705397834000},"source":"Crossref","is-referenced-by-count":3,"title":["Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias \u2013 A Single Centre Experience."],"prefix":"10.46989","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-7229","authenticated-orcid":false,"given":"Allison C. Y.","family":"Tso","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d59j24","id-type":"ROR","asserted-by":"publisher"}],"name":"Tan Tock Seng Hospital","department":["Haematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1013-7364","authenticated-orcid":false,"given":"Samuel S. Y.","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d59j24","id-type":"ROR","asserted-by":"publisher"}],"name":"Tan Tock Seng Hospital","department":["Haematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5048-4259","authenticated-orcid":false,"given":"Christian A.","family":"Gallardo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d59j24","id-type":"ROR","asserted-by":"publisher"}],"name":"Tan Tock Seng Hospital","department":["Haematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-4628","authenticated-orcid":false,"given":"Dheepa","family":"Christopher","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d59j24","id-type":"ROR","asserted-by":"publisher"}],"name":"Tan Tock Seng Hospital","department":["Haematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7646-3591","authenticated-orcid":false,"given":"Kiat Hoe","family":"Ong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/032d59j24","id-type":"ROR","asserted-by":"publisher"}],"name":"Tan Tock Seng Hospital","department":["Haematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"ref1","article-title":"MOH will act to manage cancer drug costs where necessary","year":"2023","journal-title":"Ministry of Health, Singapore"},{"key":"ref2","article-title":"A Study to Compare the PK, Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects. ClinicalTrials.gov Identifier: NCT05679258"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study","volume":"192","author":"Ajai Chari","year":"2021","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Michel de Weers","year":"2011","journal-title":"The Journal of Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Marije B Overdijk","year":"2015","journal-title":"mAbs","ISSN":"https:\/\/id.crossref.org\/issn\/1942-0862","issn-type":"print"},{"issue":"21","key":"ref6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1182\/blood.v120.21.2974.2974","article-title":"Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.","volume":"120","author":"J. H. Marco Jansen","year":"2012","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/nejmoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Efstathios Kastritis","year":"2021","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Saad Z. Usmani","year":"2016","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"8","key":"ref9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/nejmoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Antonio Palumbo","year":"2016","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"14","key":"ref10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/nejmoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Meletios A. Dimopoulos","year":"2016","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1186\/s12913-021-06919-x","article-title":"How can we improve patients\u2019 access to new drugs under uncertainties? : South Korea\u2019s experience with risk sharing arrangements","volume":"21","author":"Boram Lee","year":"2021","journal-title":"BMC Health Services Research","ISSN":"https:\/\/id.crossref.org\/issn\/1472-6963","issn-type":"print"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"921093","DOI":"10.3389\/fpubh.2022.921093","article-title":"Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study","volume":"10","author":"Hong Zhu","year":"2022","journal-title":"Frontiers in Public Health","ISSN":"https:\/\/id.crossref.org\/issn\/2296-2565","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/92085-tolerability-of-daratumumab-amongst-asian-patients-with-plasma-cell-dyscrasias-a-single-centre-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:46:14Z","timestamp":1750077974000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/92085-tolerability-of-daratumumab-amongst-asian-patients-with-plasma-cell-dyscrasias-a-single-centre-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.92085","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}